Erratum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel (Nature Communications (2015) 6 (8746) DOI: 10.1038/ncomms9746);IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wee, Zhen Ning ^a   Yatim, Siti Maryam J M ^a   Kohlbauer, Vera K ^a   Feng, Min ^a   Goh, Jian Yuan ^a   Yi, Bao ^a   Lee, Puay Leng ^a   Zhang, Songjing ^a   Wang, Pan Pan ^b   Lim, Elgene ^c   Tam, Wai Leong ^a,d   Cai, Yu ^b   Ditzel, Henrik J ^e,f   Hoon, Dave S B ^g   Tan, Ern Yu ^h   Yu, Qiang ^a,b,i,j  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b JINAN UNIVERSITY   (China)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g JOHN WAYNE CANCER INSTITUTE   (United States)

^h TAN TOCK SENG HOSPITAL   (Singapore)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j DUKE NUS MEDICAL SCHOOL   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER; GENE EXPRESSION; HORMONE; RABIES; SECRETION; TUMOR;

ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; PACLITAXEL;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MICE; MICE, SCID; NEOPLASM METASTASIS; PACLITAXEL; PHOSPHORYLATION;

EID: 84946056925     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10054     Document Type: Erratum

References (50)

1. Cleator, S., Heller, W. & Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8, 235-244 (2007
2. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010
3. Clevers, H. At the crossroads of inflammation and cancer. Cell 118, 671-674 (2004
4. Rakoff-Nahoum, S. & Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer 9, 57-63 (2009
5. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002
6. Basseres, D. S. & Baldwin, A. S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817-6830 (2006
7. Jost, P. J. & Ruland, J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109, 2700-2707 (2007
8. Perkins, N. D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012
9. Hartman, Z. C. et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73, 3470-3480 (2013
10. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012
11. Yamamoto, M. et al. NF-kappaB non-cell-Autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun. 4, 2299 (2013
12. Ginestier, C. et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120, 485-497 (2010
13. Baud, V. & Karin, M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33-40 (2009
14. Dutta, J., Fan, Y., Gupta, N., Fan, G. & Gelinas, C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25, 6800-6816 (2006
15. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-kappaB signaling: balancing life and death-A new approach to cancer therapy. J. Clin. Invest. 115, 2625-2632 (2005
16. DiDonato, J. A., Mercurio, F. & Karin, M. NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 246, 379-400 (2012
17. Tornatore, L. et al. Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta/MKK7 inhibitors. Cancer Cell 26, 495-508 (2014
18. Rhyasen, G. W. et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90-104 (2013
19. Srivastava, R. et al. Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 72, 6209-6216 (2012
20. Li, Z. et al. Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J. Clin. Invest. 125, 1081-1097 (2015
21. Scheeren, F. A. et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. Nat. Cell Biol. 16, 1238-1248 (2014
22. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003
23. Tam, W. L. et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347-364 (2013
24. Korkaya, H., Liu, S. & Wicha, M. S. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin. Cancer Res. 17, 6125-6129 (2011
25. Lu, H. et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 16, 1105-1117 (2014
26. Barbie, T. U. et al. Targeting an IKBKE cytokine network impairs triplenegative breast cancer growth. J. Clin. Invest. 124, 5411-5423 (2014
27. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005
28. Chiang, E. Y., Yu, X. & Grogan, J. L. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types. J. Immunol. 186, 1279-1288 (2011
29. Rajan, P. & Srinivasan, R. Targeting cancer stem cells in cancer prevention and therapy. Stem Cell Rev. 4, 211-216 (2008
30. Sistigu, A. et al. Cancer cell-Autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301-1309 (2014
31. Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213 (2015
32. Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L. & Semenza, G. L. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc. Natl Acad. Sci. USA 111, E5429-E5438 (2014
33. Steiner, R. et al. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur. J. Cancer Clin. Oncol. 19, 1553-1557 (1983
34. Wada, T. & Penninger, J. M. Mitogen-Activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849 (2004
35. Cai, B., Chang, S. H., Becker, E. B., Bonni, A. & Xia, Z. p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J. Biol. Chem. 281, 25215-25222 (2006
36. Chuang, S. M., Wang, I. C. & Yang, J. L. Roles of JNK, p38 and ERK mitogen-Activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis 21, 1423-1432 (2000
37. Thomas, L. W., Lam, C. & Edwards, S. W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 584, 2981-2989 (2010
38. Petrocca, F. et al. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24, 182-196 (2013
39. Joh, E. H., Lee, I. A., Jung, I. H. & Kim, D. H. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation-the key step of inflammation. Biochem. Pharmacol. 82, 278-286 (2011
40. Liu, M. et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464-10473 (2010
41. Murohashi, M. et al. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. Br. J. Cancer 102, 206-212 (2010
42. Huang, Y., Li, T., Sane, D. C. & Li, L. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J. Biol. Chem. 279, 51697-51703 (2004
43. Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735 (2011
44. Bhola, N. E. et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348-1358 (2013
45. Wu, X. et al. Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc. Natl Acad. Sci. USA 111, 13870-13875 (2014
46. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002
47. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-5413 (2008
48. Kollewe, C. et al. Sequential autophosphorylation steps in the interleukin-1 receptor-Associated kinase-1 regulate its availability as an adapter in interleukin-1 signaling. J. Biol. Chem. 279, 5227-5236 (2004
49. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675 (2012
50. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Br. Cancer Res. Treat. 123, 725-731 (2010